AOD-9604 is a modified C-terminal fragment of human growth hormone with genuine lipolytic activity in mice. Metabolic Pharmaceuticals ran it through two Phase 3 trials for obesity — it did not beat placebo. The company subsequently dissolved. This is not a suppression story; it is a drug that did not work in humans after showing promise in rodents, which is extremely common in pharmaceutical development. The "Big Pharma buried it" narrative requires you to believe that Novo Nordisk spent 30 years and $6 billion developing semaglutide — which actually works — while simultaneously suppressing a mouse peptide that failed its own trials. The molecule is currently sold on research chemical sites citing the pre-Phase 3 rodent data. Every citation that appears to support the "buried" claim predates the clinical failures. Read the 2014 Phase 3 results, then read the forums.